Finding a new way to predict outcomes for patients with oropharynx cancer
Validation of a clinically accessible prognostic biomarker for oropharynx cancer using molecular and spatial data
This study is looking to find a new way to help doctors predict how oropharynx cancer might affect patients, especially those with HPV-positive tumors, so they can tailor treatments better and avoid giving unnecessary side effects to those who might not need them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11040101 on NIH RePORTER |
What this research studies
This research aims to validate a new prognostic biomarker for oropharynx cancer (OPC) that can help identify patients at risk for adverse outcomes, such as recurrence or death. By analyzing tumor biology and heterogeneity in over 1,000 HPV-positive OPC patients from various regions, the study seeks to improve clinical decision-making and reduce unnecessary treatment-related side effects. The approach involves using molecular and spatial data to create a reliable scoring system that can be applied across diverse patient populations. This biomarker could ultimately guide treatment strategies, allowing for more personalized care.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HPV-positive oropharynx cancer who are undergoing treatment.
Not a fit: Patients with HPV-negative oropharynx cancer or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of treatment outcomes for patients with oropharynx cancer, enabling tailored therapies that minimize toxicity.
How similar studies have performed: Previous research has shown promise in using biomarkers for cancer prognosis, suggesting that this approach could yield significant advancements in treatment strategies.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Puram, Sidharth Venkata — Washington University
- Study coordinator: Puram, Sidharth Venkata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.